Sensei Biotherapeutics, Inc. Common Stock (SNSE) Stock Price
SNSEStock
$34.71+359.97%52W
Market Cap$46.58M
P/E—
PEG Ratio—
Div yield—
Beta-0.31
SNSE Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)20.98%
Price vs S&P 500 (4W)16.10%
VGM Score84.58
SNSE Earnings Surprise History
Q2 25-3.91est. -5.00
Q3 25-3.62est. -4.11
Q4 25-3.74est. -4.81
Q1 26-131.45est. -0.62
SNSE Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
2.17
2.17
4.13
4.20
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SNSESensei Biotherapeutics, Inc. Common Stock | — | — | A | $34.71 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Sensei Biotherapeutics, Inc. Common Stock
Sensei Biotherapeutics is an immuno-oncology company developing next-generation cancer therapeutics through its TMAb (Tumor Microenvironment Activated Biologics) platform, which targets immunosuppressive and immunostimulatory signals within tumors. The company has four clinical-stage candidates in development: SNS-101 (VISTA), SNS-102 (VSIG4), SNS-103 (ENTPDase/CD39), and SNS-201 (VISTAxCD28). This targeted approach aims to improve outcomes for cancer patients by modulating the tumor microenvironment.